Solidification of Carvedilol (cas 72956-09-3) loaded SMEDDS by swirling fluidized bed pellet coating
-
Add time:07/20/2019 Source:sciencedirect.com
Self-(micro)emulsifying drug delivery systems (S(M)EDDS) have emerged as effective vehicles for enhancing bioavailability of poorly water soluble drugs, however solidification of the systems represents a major challenge. Objective of this study was development of Carvedilol (cas 72956-09-3) loaded liquid SMEDDS and transformation into solid pellets employing fluid-bed coating technologies. Carvedilol-loaded formulation of SMEDDS was comprised of Capmul® MCM EP, castor oil, Kolliphor® RH40 and PEG 400. The obtained liquid SMEDDS mixed with fillers and polymers was layered onto MCC pellets. Coating process was conducted in the modified, swirl-flow based fluid bed coating device, which was proved superior over the conventional Wurster fluid bed, with lower agglomeration rate. Use of polymer was essential for entrapping SMEDDS in the coating layer(s). Self-microemulsifying properties as well as fast drug release as one of main SMEDDS advantages were preserved in the solid products. Addition of lactose into the coating dispersion and applying intermediate and surface film coating to the pellets enabled higher drug loading and prevented sticking of the pellets during handling and storage. Present study indicates that the (swirling) fluid-bed pellet coating technology is a promising strategy for preparation of solid SMEDDS-coated pellets with adequate drug loading capacity and enhanced release of poorly water soluble drug.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
Prev:Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin
Next:Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study07/22/2019
- Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin07/21/2019
- Carvedilol (cas 72956-09-3) attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling07/19/2019
- Carvedilol (cas 72956-09-3) and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction07/18/2019
- Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells07/17/2019
- Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process07/16/2019
- The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway07/15/2019
- Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis07/14/2019
- The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo07/13/2019
-
Health and Chemical more >
-
Related Products